Catalent Speeds Up Complex Biologics Development with 10-Month Gene-to-Drug Program
Event summary
- Catalent launched an accelerated gene-to-drug substance program for complex biologics in the U.S., targeting a 10-month timeline.
- The program leverages GPEx® Lightning cell line development technology and integrated U.S. manufacturing workflows.
- Key milestones include master cell bank release by month 7 and bulk drug substance shipment by month 9.
- Complements existing 8-month Rapid Antibody program for traditional monoclonal antibodies (mAbs).
The big picture
Catalent's new program addresses the industry shift toward more complex biologics, where development timelines have traditionally lagged behind standard monoclonal antibodies. By offering predictable, accelerated paths for both traditional and complex molecules, Catalent positions itself as a key enabler for biotech companies racing to bring advanced therapies to market. The move underscores the growing importance of speed in biopharmaceutical development, particularly for treatments targeting serious conditions.
What we're watching
- Market Adoption
- How quickly biotech developers will adopt this accelerated program for complex molecules.
- Competitive Response
- Whether competitors like Lonza or Samsung Biologics will match this speed for complex biologics.
- Regulatory Efficiency
- The pace at which U.S. regulators will adapt to faster development timelines for next-generation biologics.
